San Diego—For front-line therapy of follicular lymphoma (FL), an obinutuzumab-based induction and maintenance protocol provides greater progression-free survival (PFS) than a rituximab-based regimen, according to a head-to-head Phase III trial. In the multinational trial, called GALLIUM, the rate of adverse events (AEs) was generally higher in the obinutuzumab arm, but the benefits, such as increased time to next treatment (TTNT), support the premise that obinutuzumab provides more